Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3054667 26 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression
in patients with malignant melanoma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Aim: Use of molecular markers indicative of the tumour oncogenic
potential and host response may enhance our prognostic information for
more effective treatment of melanoma patients. The roles of HSP-70
protein, c-myc oncogene and HLA-DR antigen expression were examined in
melanoma patients and related to prognostic factors, recurrence rate and
long-term survival.
Methods: Forty patients with tumours thicker than I mm were included in
this study. All had elective node dissection and were followed for at
least 7 years. Twenty-two had microscopic nodal metastases. Both primary
melanoma tumour and lymph nodes were examined for the
immunohistochemical expression of HSP-70 protein, c-myc oncogene and
HLA-DR antigen.
Results: Eighteen patients had a recurrence (45%) and 23 patients
survived overall (57.50%). Positive HSP-70 expression was observed in
52.50% of the primary melanomas and was associated with improved
overall survival, especially in the patient group with tumours greater
than or equal to1.5 mm (70% vs 26.70%, P = 0.0159). C-myc oncogene was
overexpressed in 47.50% and HLA-DR antigen in 42.50% of the primary
melanomas, but no correlation with survival was observed. The expression
profile of these molecular markers in the primary tumour did not predict
the status of regional nodes. HLA-DR expression in lymph nodes was
observed exclusively in the nodal tissue surrounding the metastatic
melanoma tumour in five patients.
Conclusions: The immunohistochemical expression profile of HSP-70 but
not of c-myc oncogene or HLA-DR antigen in the primary melanoma tumour
could be of certain value in the identification of patients with graver
prognosis who may benefit from more aggressive therapeutic strategies,
(C) 2001 Harcourt Publishers Ltd.
Έτος δημοσίευσης:
2001
Συγγραφείς:
Ricaniadis, N
Kataki, A
Agnantis, N
Androulakis, G and
Karakousis, CP
Περιοδικό:
European Journal of Surgical Oncology
Εκδότης:
W B SAUNDERS CO LTD
Τόμος:
27
Αριθμός / τεύχος:
1
Σελίδες:
88-93
Λέξεις-κλειδιά:
malignant melanoma; molecular markers; host response
Επίσημο URL (Εκδότης):
DOI:
10.1053/ejso.1999.1018
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.